STAHL'S ESSENTIAL
PSYCHOPHARMACOLOGY
NEUROSCIENTIFIC BASIS AND PRACTICAL
APPLICATIONS
5TH EDITION
AUTHOR(S)STEPHEN M. STAHL
TEST BANK
1
Reference: Ch. 1 — Chemical Neurotransmission — Presynaptic
Vesicular Storage and VMAT
Stem: A 45-year-old patient with Parkinsonism and severe
depressive symptoms has been receiving a medication known
to deplete vesicular monoamine stores. Their depression
appears refractory to an SSRI started 6 weeks ago.
Mechanistically, which intervention best addresses the
,presynaptic deficit to restore synaptic monoamine availability
and potentially improve antidepressant response?
A. Increase the SSRI dose to further block neuronal reuptake.
B. Stop the vesicular-depleting agent and allow resynthesis of
vesicular stores before continuing SSRI.
C. Add a monoamine oxidase inhibitor (MAOI) to reduce
enzymatic breakdown in the cytosol.
D. Add a dopamine D2 receptor antagonist to block
autoreceptor feedback.
Correct answer: B
Rationale — Correct (B): VMAT blockade depletes vesicular
stores so there is little transmitter available for release;
removing the vesicular-depleting agent permits vesicular
resynthesis and restoration of physiologic release. This
mechanistic fix targets presynaptic storage rather than
modifying reuptake or metabolism downstream, aligning with
Stahl’s presentation of vesicular storage as essential for synaptic
transmission.
Rationale — Incorrect (A): Increasing SSRI will block reuptake
but cannot increase released transmitter if vesicular stores are
depleted.
Rationale — Incorrect (C): MAOI decreases cytosolic
breakdown but with VMAT blockade cytosolic monoamine may
be low and MAOI risks (e.g., hypertensive effects) without fixing
vesicular release.
Rationale — Incorrect (D): D2 antagonism could increase
,dopamine release in intact systems but won’t restore depleted
vesicular stores and may worsen extrapyramidal signs.
Teaching point: Fix presynaptic storage deficits before
escalating downstream pharmacologic manipulations.
Citation: Stahl, S. M. (2024). Stahl’s Essential
Psychopharmacology: Neuroscientific Basis and Practical
Applications (5th ed.). Ch. 1.
2
Reference: Ch. 1 — Chemical Neurotransmission —
Transporters and Reuptake
Stem: A patient with major depression partially responds to an
SSRI but continues to have severe fatigue and poor
concentration suggestive of inadequate noradrenergic tone.
From a synaptic-mechanism perspective, which medication
change best addresses deficient norepinephrine reuptake while
preserving serotonergic effects?
A. Switch to an SNRI with balanced SERT and NET inhibition.
B. Add a dopamine D2 partial agonist to increase
catecholaminergic tone.
C. Add an acetylcholinesterase inhibitor to enhance cholinergic
neuromodulation.
D. Augment with a benzodiazepine to reduce anxious arousal
and increase focus indirectly.
, Correct answer: A
Rationale — Correct (A): An SNRI inhibits NET as well as SERT,
increasing extracellular norepinephrine in synaptic clefts and
addressing concentration/fatigue via enhanced noradrenergic
neurotransmission. Stahl emphasizes transporter selectivity as a
way to shift monoaminergic balance.
Rationale — Incorrect (B): D2 partial agonists mainly affect
dopaminergic signaling; they do not directly inhibit NET and
thus are less targeted for noradrenergic deficits.
Rationale — Incorrect (C): Acetylcholinesterase inhibitors
increase acetylcholine, which may worsen depression in some
and do not directly correct noradrenergic reuptake deficits.
Rationale — Incorrect (D): Benzodiazepines modulate GABA_A
receptors and reduce anxiety but do not enhance NET function;
they can impair concentration.
Teaching point: Choose agents by transporter profile to target
specific monoamine deficits.
Citation: Stahl, S. M. (2024). Stahl’s Essential
Psychopharmacology: Neuroscientific Basis and Practical
Applications (5th ed.). Ch. 1.
3
Reference: Ch. 1 — Chemical Neurotransmission —
Autoreceptors and Heteroreceptors
PSYCHOPHARMACOLOGY
NEUROSCIENTIFIC BASIS AND PRACTICAL
APPLICATIONS
5TH EDITION
AUTHOR(S)STEPHEN M. STAHL
TEST BANK
1
Reference: Ch. 1 — Chemical Neurotransmission — Presynaptic
Vesicular Storage and VMAT
Stem: A 45-year-old patient with Parkinsonism and severe
depressive symptoms has been receiving a medication known
to deplete vesicular monoamine stores. Their depression
appears refractory to an SSRI started 6 weeks ago.
Mechanistically, which intervention best addresses the
,presynaptic deficit to restore synaptic monoamine availability
and potentially improve antidepressant response?
A. Increase the SSRI dose to further block neuronal reuptake.
B. Stop the vesicular-depleting agent and allow resynthesis of
vesicular stores before continuing SSRI.
C. Add a monoamine oxidase inhibitor (MAOI) to reduce
enzymatic breakdown in the cytosol.
D. Add a dopamine D2 receptor antagonist to block
autoreceptor feedback.
Correct answer: B
Rationale — Correct (B): VMAT blockade depletes vesicular
stores so there is little transmitter available for release;
removing the vesicular-depleting agent permits vesicular
resynthesis and restoration of physiologic release. This
mechanistic fix targets presynaptic storage rather than
modifying reuptake or metabolism downstream, aligning with
Stahl’s presentation of vesicular storage as essential for synaptic
transmission.
Rationale — Incorrect (A): Increasing SSRI will block reuptake
but cannot increase released transmitter if vesicular stores are
depleted.
Rationale — Incorrect (C): MAOI decreases cytosolic
breakdown but with VMAT blockade cytosolic monoamine may
be low and MAOI risks (e.g., hypertensive effects) without fixing
vesicular release.
Rationale — Incorrect (D): D2 antagonism could increase
,dopamine release in intact systems but won’t restore depleted
vesicular stores and may worsen extrapyramidal signs.
Teaching point: Fix presynaptic storage deficits before
escalating downstream pharmacologic manipulations.
Citation: Stahl, S. M. (2024). Stahl’s Essential
Psychopharmacology: Neuroscientific Basis and Practical
Applications (5th ed.). Ch. 1.
2
Reference: Ch. 1 — Chemical Neurotransmission —
Transporters and Reuptake
Stem: A patient with major depression partially responds to an
SSRI but continues to have severe fatigue and poor
concentration suggestive of inadequate noradrenergic tone.
From a synaptic-mechanism perspective, which medication
change best addresses deficient norepinephrine reuptake while
preserving serotonergic effects?
A. Switch to an SNRI with balanced SERT and NET inhibition.
B. Add a dopamine D2 partial agonist to increase
catecholaminergic tone.
C. Add an acetylcholinesterase inhibitor to enhance cholinergic
neuromodulation.
D. Augment with a benzodiazepine to reduce anxious arousal
and increase focus indirectly.
, Correct answer: A
Rationale — Correct (A): An SNRI inhibits NET as well as SERT,
increasing extracellular norepinephrine in synaptic clefts and
addressing concentration/fatigue via enhanced noradrenergic
neurotransmission. Stahl emphasizes transporter selectivity as a
way to shift monoaminergic balance.
Rationale — Incorrect (B): D2 partial agonists mainly affect
dopaminergic signaling; they do not directly inhibit NET and
thus are less targeted for noradrenergic deficits.
Rationale — Incorrect (C): Acetylcholinesterase inhibitors
increase acetylcholine, which may worsen depression in some
and do not directly correct noradrenergic reuptake deficits.
Rationale — Incorrect (D): Benzodiazepines modulate GABA_A
receptors and reduce anxiety but do not enhance NET function;
they can impair concentration.
Teaching point: Choose agents by transporter profile to target
specific monoamine deficits.
Citation: Stahl, S. M. (2024). Stahl’s Essential
Psychopharmacology: Neuroscientific Basis and Practical
Applications (5th ed.). Ch. 1.
3
Reference: Ch. 1 — Chemical Neurotransmission —
Autoreceptors and Heteroreceptors
